Differential localization of type I and type II benzodiazepine binding sites in substantia nigra.
A number of studies have suggested the existence of multiple benzodiazepine binding sites in the brain. We have recently reported the physical separation of two apparent benzodiazepine binding site subtypes, the pharmacological properties, and distribution in tissue sections of which correspond to the putative type I and type II sites. Benzodiazepine and gamma-aminobutyric acid (GABA) receptors have been shown to interact, and lesions of the GABAergic striatonigral pathway, which lead to GABA supersensitivity, both increase the numbers of GABA binding sites and enhance GABA-stimulated benzodiazepine binding. We demonstrate here that degeneration of striatonigral fibres increases the density of putative type I benzodiazepine binding sites in the substantia nigra and decreases the density of the putative type II sites. This suggests that type I sites that increase after denervation are postsynaptic, whereas the type II sites reduced by the lesion may be localized to axons or terminals of the striatonigral pathways.
D000818:Animals; D001569:Benzodiazepines / Q000378:metabolism; D001667:Binding, Competitive; D002421:Caudate Nucleus / Q000502:physiology; D003342:Corpus Striatum / Q000378:metabolism; D005445:Flunitrazepam; D009434:Neural Pathways / Q000502:physiology; D011724:Pyridazines; D051381:Rats; D011956:Receptors, Cell Surface / Q000145:classification / Q000378:metabolism*; D011963:Receptors, GABA-A; D013378:Substantia Nigra / Q000378:metabolism*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D011724:Pyridazines; D011956:Receptors, Cell Surface; D011963:Receptors, GABA-A; D001569:Benzodiazepines; D005680:gamma-Aminobutyric Acid; D005445:Flunitrazepam; C021604:CL 218872